January 09, 2008 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announces the publication of a positive peer-reviewed paper on the clinical utility of the Company’s AlzheimAlert™ urine test as an aid to physicians in the diagnosis of Alzheimer’s disease in the current issue of Expert Review of Molecular Diagnostics (January 2008; 8:21-28). The paper, entitled “Practical utility of urinary assay in the diagnosis of Alzheimer's disease: AlzheimAlert™,” is authored by Ira Goodman, MD, the Director of Neurology, Orlando Regional HealthCare, Florida, and Associate Clinical Professor, Departments of Neurology & Medicine, University of Florida School of Medicine... [PDF] Nymox's Press Release -
Blog Archive
-
▼
2008
(79)
-
▼
January
(8)
- Medivation, Pivotal Confirmatory Phase 3 Trial of ...
- Neuronetrix , COGNISION, Tests New Device to Scree...
- CoMentis , Proof-of-Activity-Data from its Phase I...
- Nymox Alzheimer Test, Positive Report
- Prana, Phase IIa Trial of PBT2 in Alzheimer's Dise...
- Allon Therapeutics, Phase II clinical trial in Alz...
- Elan and Transition Therapeutics, Phase 2 Clinical...
- Elan and Wyeth, Phase 3 Program for Bapineuzumab (...
-
▼
January
(8)